Revenue breakdown: Med Device Segment (64.7%), Med Tech Segment (35.3%).
8-K
AngioDynamics reported fiscal Q3 2026 net sales of $78.4 million (+8.9% YoY) and raised its full-year FY2026 guidance for net sales and Adjusted EBITDA, driven by 19.0% growth in its Med Tech segment.